Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 79

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 79
---
 or 3.0% of the gross proceeds of the Initial Public Offering, or $6,900,000 in the aggregate,
of which 25.0% will be adjusted net of redemptions (i.e., for purposes of calculating the deferred underwriting commission net of redemptions,
25.0% of the deferred underwriting commissions will determined by the dollar amount that is product of (i) 3.0% multiplied by the product
of the number of unredeemed public shares, multiplied by $10.00 and (ii) 25.0%). The deferred fee becomes payable to the underwriters
from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms
of the underwriting agreement. In addition, the Company agreed to issue the underwriters 230,000 ordinary shares, denoted as representative
shares.

NOTE
7 — SHAREHOLDERS’ DEFICIT

Preference
Shares — The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share
with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of
directors. As of September 30, 2025 and December 31, 2024, there were no preference shares issued or outstanding.

Ordinary
Shares — The Company is authorized to issue 220,000,000 ordinary shares with a par value of $0.0001 per share.
Holders of ordinary shares are entitled to one vote for each share. As of September 30, 2025 and December 31, 2024, there are 10,517,143
and 9,857,143 ordinary shares issued and outstanding, excluding 23,000,000 and 0 share subject to redemption, respectively. Of the ordinary
shares outstanding at December 31, 2024, an aggregate of up to 1,285,714 ordinary shares were subject to surrender and forfeiture to
the extent that the underwriters’ over-allotment option was not exercised in full or in part so that the number of Founder Shares
would equal 30% of the Company’s issued and outstanding ordinary shares after the Initial Public Offering (not including the Private
Placement Units and the representative shares and assuming Sponsor does not purchase any Public Shares in the Initial Public Offering).
In February 2025 the over-all